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Background: Thyroid hormone supplementation anecdotally has been described as a valid treat-
ment option for dogs with aggression-related problems. However, prospective, controlled, and
blinded trials evaluating behavior and neurohormonal status in hypothyroid dogs during treat-
ment with levothyroxine are lacking.
Objective: Levothyroxine supplementation will have a significant influence on the behavior and
neurohormonal status of dogs with spontaneous hypothyroidism.
Animals: Twenty client-owned dogs diagnosed with spontaneous hypothyroidism.
Methods: This prospective study was to evaluate the behavior of dogs, which was screened at
initial presentation, and after 6 weeks, and 6 months of treatment with levothyroxine (starting
dosage 10 μg/kg PO q12h) using the standardized Canine Behavioral Assessment and
Research Questionnaire (C-BARQ). At each time period, circulating serotonin and prolactin
(PRL) concentrations were evaluated using a commercially validated ELISA kit and heterolo-
gous radioimmunoassay, respectively.
Results: After 6 weeks of thyroid hormone supplementation, C-BARQ scores demonstrated a
significant increase in activity of hypothyroid dogs (P < .01). No significant change in any of the
behavioral signs was observed after 6 months of treatment. No significant difference in circulat-
ing concentrations of serotonin (P > .99 and P = .46) and PRL (P = .99 and P = .37) were noted
between the 6-week and 6-month periods compared with baseline.
Conclusions and Clinical Importance: The results of this study indicate increased activity of
hypothyroid dogs after 6 weeks of thyroid hormone supplementation. None of the hypothyroid
dogs in this cohort showed a significant change in any of the evaluated behavioral signs and
neurohormonal status after 6 months of thyroid hormone supplementation.
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1 | INTRODUCTION
Mental dullness and lethargy are 2 of the most frequently documen-
ted behavioral abnormalities in hypothyroid dogs, which typically
resolve within a few weeks of thyroid hormone supplementation.1 A
few authors also suggested an increase in irritability and unprovoked
aggression towards animals and people in some hypothyroid dogs,
which improved with combined levothyroxine and behavioral
treatment.2–6 A recent randomized placebo-controlled study also
described decreased owner-directed aggression after the start of thy-
roid hormone supplementation in “borderline hypothyroid” dogs.7 In
contrast, recent case-controlled and cross-sectional studies failed to
show abnormalities in several thyroid analytes in dogs with behavioral
Abbreviations: 5HT, 5-hydroxytryptamine; C-BARQ, Canine Behavioral Assess-
ment and Research Questionnaire; CSF, cerebrospinal fluid; fT3, free triiodothy-
ronine; fT4, free thyroxine; PRL, prolactin; TgAA, thyroglobulin antibodies; TRH,
thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; TT4, total
thyroxine; TT3, total triiodothyronine.
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and aggression-related problems.8,9 Based on these reports, a stan-
dardized evaluation of temperament and behavior and the effect of
thyroid hormone supplementation on behavior in hypothyroid dogs
is required.
Involvement of the serotonergic system in dogs with aggression
has been established in several reports based on the measurement of
serotonin concentrations in blood or cerebrospinal fluid (CSF), func-
tional brain imaging, or by the successful use of drugs influencing
serotonergic neurotransmission, namely selective serotonin reuptake
inhibitors.10–16 Thyroid hormones appear to affect the concentrations
of serotonin in blood and different brain regions and modulate seroto-
nin turnover in the brain.17,18 These mechanisms have been studied
extensively in humans and in animal models, but none of the studies
has evaluated the effect of thyroid hormone supplementation on the
serotonergic system in dogs.
Another neuroprotein affected by thyroid hormones is prolactin
(PRL). In addition to its mammotropic and lactogenic properties, PRL
also has a complex effect on neuroendocrine and behavioral adapta-
tions, and has been associated with maternal aggression in female
dogs.19,20 Thyrotropin-releasing hormone (TRH) has been shown to
stimulate PRL gene expression and PRL release from lactotrophs in a
dose-dependent manner.21 Hyperprolactinemia and thyroid-
stimulating hormone (TSH) at the high end of the reference range also
have been documented in women diagnosed with hypothyroidism;
however, further studies failed to document aggressive behavior or
mood disorders in these groups of women.21,22 In dogs, aggression
associated with hyperprolactinemia has mostly been associated with
pseudopregnancy, although no study has examined PRL concentra-
tions in otherwise aggressive dogs.20
Based on this information, the first aim of our prospective study
was to evaluate the behavior of dogs with spontaneous hypothyroid-
ism during treatment with levothyroxine using a standardized canine
behavioral questionnaire. A second aim was to evaluate circulating
serotonin and PRL concentrations during thyroid hormone
supplementation.
2 | MATERIALS AND METHODS
2.1 | Animals
Client-owned dogs of various breeds, ages, and body weights were
prospectively included in this study. Dogs consisted of both first opin-
ion and referral cases (ie, dogs presented or referred to the Small Ani-
mal Department, Faculty of Veterinary Medicine, Ghent University,
and Department of Clinical Sciences of Companion Animals, Faculty
of Veterinary Medicine, Utrecht University). For dogs recruited from
first opinion practices and for referral cases, the same exclusion and
inclusion criteria applied. The owners of the dogs were blinded to the
aims of the study and were told that the objective of the study was to
investigate the quality of life of dogs with hypothyroidism during thy-
roid hormone supplementation.
To be included in the study, dogs had to have clinical and labora-
tory variables consistent with hypothyroidism (ie, physical examination
[PE] findings and routine laboratory examinations including hematology
and serum biochemistry).
All participating practitioners received an information brochure
and checklist summarizing the aims of the study and the inclusion and
exclusion criteria. Once the checklist was reviewed and the dogs ful-
filled all of the inclusion criteria, participating practices were provided
with the sampling material and instructions on the sampling, proces-
sing, and storage of samples. Compliance with the study criteria was
controlled by means of regular follow-up phone calls and email
remainders.
Disorders unrelated to hypothyroidism were ruled out based
on thorough history, PE, hematology, and serum biochemistry pro-
files. Dogs were excluded from the study if they had received any
medication within 2 months before inclusion and throughout the
duration of the study except the following: flea and heartworm pro-
phylaxis, routine vaccination, topical antifungals (eg, ketoconazole,
itraconazole), PO antibiotics except sulfonamides, and topical ear
solutions that did not contain glucocorticoids. Pregnant dogs and
dogs suffering from any concurrent systemic disorder also were
excluded.
2.2 | Diagnosis and treatment of hypothyroidism
The diagnosis of hypothyroidism had to be confirmed by finding a circu-
lating total thyroxine (TT4) concentration <1.2 μg/dL and a circulating
TSH concentration >0.6 ng/mL. In cases in which the TT4 and TSH con-
centrations were not conclusive, the diagnosis was confirmed by a TSH
stimulation test or scintigraphic assessment of the thyroid function.
The TSH response test was performed using 150 μg of freshly reconsti-
tuted or frozen recombinant human TSH as previously described.23–25
For scintigraphic assessment of thyroid function for diagnosing hypothy-
roidism, dogs with very low or absent technetium-99m pertechnetate
uptake during thyroid scintigraphy were considered hypothyroid.26
After the diagnosis was confirmed (T0), all dogs were started on
treatment with levothyroxine sodium (Forthyron; Eurovet Animal
Health B.V., Bladel, The Netherlands; starting dosage, 10 μg/kg PO
q12h). Follow-up appointments were scheduled at 6 weeks (T1) and
6 months (T2) after the start of treatment. The goal of treatment was
to obtain a peak TT4 concentration, 2-4 hours after administration of
levothyroxine, at the high end of or slightly above the upper limit of
the reference interval. For therapeutic monitoring, if levothyroxine
was given at the time of feeding, the same protocol was followed on
the day of testing. If dose adjustment at 6 weeks was needed, it was
left at the discretion of the clinician, and another control was planned
a month later.
2.3 | Evaluation of behavior
The behavior of dogs was evaluated at T0, T1, and T2 by having the
owners complete a hard copy of the Canine Behavioral Assessment
and Research Questionnaire (C-BARQ). The C-BARQ is a standardized
owner-completed online questionnaire (http://www.cbarq.org)
designed to provide quantitative assessments of numerous behavioral
and temperamental characteristics of dogs.27–30 The questionnaire is
comprised of 7 general behavioral categories (ie, sociability, trainability,
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aggression, fear and anxiety, excitability, separation-related behavior,
attachment and attention-seeking behavior, and miscellaneous) and
101 scored questions evaluating dogs' typical responses to a variety of
everyday situations, stimuli, and events in their environment.27
Owners assess either the frequency or the severity of the behavioral
characteristics using a 5-point ordinal scale, with higher scores usually
being less favorable.27–30 For correct use of the scale, each section of
the questionnaire includes a brief explanation of typical behavioral
signs associated with each behavioral category that owners can recog-
nize and use when scoring their dogs.27 Documented behavioral char-
acteristics are then further compared to the behavioral characteristics
of all dogs and the dog's own breed.27,29,30
Hard copies of CBARQ were available in 4 languages (Dutch, Ger-
man, French, and English) allowing the owners to fill in the question-
naire in their native language.
2.4 | Blood sampling and storage
Blood was collected at T0, T1, and T2. Because of daily variations of
serotonin, blood samples were collected between 9 and 11 AM. Ten
milliliters of blood was collected from the jugular vein and divided
between serum and heparin tubes. During the initial presentation,
1 aliquot of ethylenediaminetetraacetic acid blood also was collected
for hematology. Serum and heparin tubes were centrifuged and fur-
ther aliquoted. One aliquot of serum was used for rapid monitoring of
TT4 concentration, performed by each of the collaborating institutions
and veterinary practices individually. Additional aliquots of serum and
heparin were frozen immediately at −20C. For storage >2 weeks,
samples were stored at −80C. Frozen serum aliquots were used for
measurement of TT4, TSH, and serotonin. Serum TT4 and TSH con-
centrations were determined using a previously validated commer-
cially available solid-phase, chemiluminescent competitive
immunoassay (Immulite 2000 Canine TSH and Total T4; Gwynedd,
United Kingdom).31,32 Frozen heparinized samples used for the mea-
surement of PRL were transported for analysis to Utrecht University
on dry ice. Upon arrival, the samples were stored at −80C until being
analyzed.
2.5 | Serotonin and PRL measurement
Serum serotonin or 5-hydroxytryptamine (5HT) concentration was
measured with the Serotonin ELISA Kit (DDD) using a commercial
enzyme immunoassay technique following the manufacturer's instruc-
tions. Measurement of serotonin was performed at the Department
of Anatomy, Histology with Embryology and Cytology, Institute of
Preclinical Sciences, Veterinary Faculty, University of Ljubljana. All
samples were run in duplicate. The assay was validated for use in
canine samples, and serotonin was calculated and expressed as previ-
ously described.33 Briefly, canine serum was spiked with increasing
concentrations of 5HT. Linearity and parallelism were assessed using
spiked canine samples and manufacturer controls for 5 different con-
centrations. Recovery was assessed as the percentage of recovered
5HT-spiked canine samples vs expected 5HT at 6 different
concentrations.33
Plasma PRL concentration was measured at Utrecht University by
using a previously validated heterologous radioimmunoactive assay.34
The intra-assay and inter-assay coefficients of variation were 3.5%
and 11.5%, respectively, and the lower limit of detection was
0.8 μg/L.
2.6 | Statistical analysis
The data were analyzed using commercial statistical software
(GraphPad Prism v7.0; GraphPad Software, La Jolla, California).
Because the data were not normally distributed, the Wilcoxon signed-
rank test for paired samples was applied to compare serum serotonin
and PRL concentrations among T0, T1, and T2. For each dog, behavior
before and on 2 occasions after the start of treatment was compared
by calculating an average score on all questions within each behavioral
category at each of the 3 occasions; a paired t test was used for com-
parison. Bonferroni's correction was applied to the data to account for
multiple pairwise comparisons resulting in a comparison-wise signifi-
cance level of 0.05/3 = 0.016.
3 | RESULTS
3.1 | Study population
Twenty dogs met the inclusion criteria. Fourteen of 20 dogs were
included from first opinion practices, and the remaining 6 dogs were
seen at the referral hospitals of University of Ghent and Utrecht. Fif-
teen dogs had circulating TT4 and TSH concentrations consistent with
primary hypothyroidism. In 2 patients, a TSH stimulation test, and, in
3 patients, thyroid scintigraphy, were used to confirm hypothyroidism.
The median age of dogs was 5.8 years (range, 2.5-11.3). There were
7 sexually intact females, 6 spayed females, 3 sexually intact males,
and 4 neutered males. Breeds included 3 crossbreeds, 2 American
Cocker Spaniels and Labrador Retrievers, and 1 each of Doberman,
Border Collie, Bullmastiff, Bavarian Mountain Hound, Golden
Retriever, Brittany Spaniel, English Cocker Spaniel, Bull Terrier, Wire-
haired Pointing Griffon, Belgian Shepherd, Airedale Terrier, Shetland
Sheepdog, and Basset Fauve De Bretagne. No abnormalities were
observed in routine hematological variables.
Of the biochemical variables, only the serum concentrations of
cholesterol (median, 528.9 mg/dL; range, 189.1-965.3 mg/dL; refer-
ence range: 111.9-386.1 mg/dL; N = 15) and triglycerides (median,
283.1 mg/dL; range, 35.4-1398.2 mg/dL; reference interval:
0-150.4 mg/dL; N = 14) were increased. For all other variables,
results were within their respective reference intervals.
The median TT4 concentration was below the reference interval
at T0 and within the reference interval (0.5-3.4 μg/dL) at T1 and T2.
The median circulating TT4 concentrations at T1 (3 μg/dL; range,
0.5-5.9 μg/dL; N = 17) and T2 (2.7 μg/dL; range, 1.6-6.4 μg/dL;
N = 16) were significantly higher (P ≤ .001) compared with that at T0
(< 0.5 μg/dL; range, < 0.5-2 μg/dL; N = 17). The median TT4 concen-
trations at T1 and T2 did not differ significantly (P = .44). Five dogs
failed to achieve euthyroidism at T1 and 2 dogs at T2.
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The median TSH concentration at T0 (1.5 ng/mL; range
0.1-12 ng/mL; N = 17) was significantly higher than those at T1
(0.12 ng/mL; range, 0.03-3.2 ng/mL; N = 17; P < .008) and T2
(0.1 ng/mL; range, 0.01-0.9 ng/mL; N = 16; P < .0001). The TSH con-
centrations between T1 and T2 did not differ significantly (P = .13).
3.2 | Evaluation of behavior
Results of the C-BARQ analysis at T0, T1, and T2 are shown in Table 1.
At T1 compared to T0, an overall significant increase (P < .01) in 1 of
7 behavioral categories (ie, activity levels) was documented. At T2, no
significant changes in any of the behavioral categories were observed
when compared with T0 and T1.
3.3 | Measurement of serotonin and PRL
The results of the serotonin and PRL concentrations are shown in
Figure 1. The median serum serotonin concentration at T0 (2221 ng/
mL; range, 426-2979 ng/mL) did not differ significantly from those at
T1 (1810 ng/mL; range, 284-2810 ng/mL; P > .99) and at T2
(1739 ng/mL; range, 226-2836; P = .46). Also, no significant differ-
ence (P = .46) was noted in the serotonin concentrations between T1
and T2. Similarly, the median plasma PRL concentration at T0 (3.3 ng/
mL; range, 1.4-6.4 ng/mL) did not differ significantly from that at T1
(3.1 ng/mL; range, 1.9-7.4 ng/mL; P = .99) and T2 (3.1 ng/mL; range,
2.0-12.9 ng/mL; P = .37). Also, no significant difference (P = .30) was
noted in PRL concentrations between T1 and T2.
4 | DISCUSSION
Our results documented a significant increase in activity in hypothy-
roid dogs after 6 weeks of thyroid hormone supplementation but
failed to show any changes in evaluated behavioral signs during
6 months of treatment. Furthermore, serum serotonin and plasma
PRL concentrations remained unchanged during thyroid hormone
supplementation.
Lethargy, mental dullness, and inactivity are the most commonly
observed clinical signs in hypothyroid dogs and are associated with
decreased metabolic rate.1 Thyroid hormone deficiency leads to a
decrease in body energy consumption followed by decreased activity
levels and lethargy.1 Appropriate thyroid hormone supplementation
therefore is expected to improve activity levels and mental alertness
of patients within a few weeks of treatment.35 A marked increase in
activity levels is usually the earliest improvement in clinical signs.35 In
humans, hypothyroidism commonly is accompanied by decreased
TABLE 1 Analysis of the C-BARQ of dogs diagnosed with primary hypothyroidism before the treatment with levothyroxine (T0; N = 20),
6 weeks (T1; N = 19) and 6 months (T2; N = 17) after initiation of treatment
a
Behavioral category
T0 and T1 T0 and T2 T1 and T2
Mean 95% CI P Mean 95% CI P Mean 95% CI P
Training −0.15 −0.27 to 0.06 .20 −0.09 −0.27 to 0.10 .33 0.04 −0.14 to 0.21 .66
Aggression −0.23 −0.46 to −0.01 .04 −0.18 −0.40 to 0.04 .10 0.05 −0.14 to 0.24 .57
Fear −0.22 −0.59 to 0.16 .24 0.02 −0.17 to 0.21 .81 0.21 −0.15 to 0.58 .23
Separation-related anxiety 0.01 −0.19 to 0.20 .95 0.01 −0.23 to 0.25 .95 0.02 −0.18 to 0.24 .80
Excitement −0.35 −0.69 to −0.2 .04 −0.20 −0.57 to 0.18 .28 0.14 −0.18 to 0.47 .37
Attachment and attention seeking −0.04 −0.40 to 0.32 .82 0.11 −0.29 to 0.51 .57 0.14 −0.16 to 0.43 .34
Activity level −0.79 −1.38 to −0.20 .01b −0.44 −1.35 to 0.47 .32 0.37 −0.42 to 1.17 .33
a Differences in behavior between T0, T1, and T2 are expressed as mean and 95% confidence interval (CI).
b Significant difference (P < 0.01).
FIGURE 1 Box and whisker plots of (A) serum serotonin
concentration of dogs diagnosed with spontaneous hypothyroidism
before (T0; N = 14) and after thyroid supplementation with
levothyroxine at 6 weeks (T1; N = 16) and 6 months (T2; N = 14)
after the start of treatment and (B) box and whisker plots of plasma
prolactin concentration of dogs with primary hypothyroidism before
(T0; N = 14) and after thyroid hormone supplementation with
levothyroxine at 6 weeks (T1; N = 18) and 6 months (T2; N = 15)
after the start of treatment. Each box and whisker plot illustrates the
median (line in the middle), mean (+), 25th and 75th percentiles (top
and bottom of each box); whiskers extend from the 5th and 95th
percentile values
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cognition, drowsiness, slower thought processes, and lethargy.18,36,37
Several, but not all, behavioral disorders in humans diagnosed with
hypothyroidism improve with thyroid hormone supplementation.38–42
Genetic factors and thyroid autoimmunity might determine individual
response to thyroid hormone supplementation in humans and
dogs.38,43
For evaluation of behavior in our study, we used a standardized
questionnaire as opposed to behavioral consultation by a specialist. A
behavioral consultation would provide more details about the dogs'
behavior and would enable us to follow up specific behavioral signs
from distant and recent history. However, statistical analysis of such
detailed information in a large number of dogs would not be possible.
The CBARQ used in our study currently is the only standardized
owner-based behavioral questionnaire allowing examination and over-
view of a large number of behavioral signs, creating data amenable to
statistical analysis.27–29,44,45
With CBARQ, our results contradict anecdotal reports supporting
the use of thyroid hormones for the treatment of aggression in
dogs.2–6 The majority of these reports either failed to conclusively
document hypothyroidism or failed to provide follow-up information
on the type and frequency of aggressive signs in dogs that achieved
euthyroidism with thyroid hormone supplementation.2–6 Furthermore,
some dogs experienced improvement of aggressive behavior but
failed to achieve euthyroidism.2 Moreover, all these dogs were treated
using behavioral treatment together with thyroid hormone supple-
mentation, which challenges the assumption that the improvement in
behavioral abnormalities could be solely attributable to thyroid hor-
mone supplementation.2–6 A recent prospective randomized placebo-
controlled study documented a decreased incidence of owner-
directed aggression of dogs with “suboptimal” thyroid function receiv-
ing thyroid hormone supplementation.7 This group of dogs showed
unprovoked owner-directed aggression several times a week and had
at least 1 nonspecific clinical sign that also may be seen in dogs with
hypothyroidism. In addition to clinical abnormalities, their thyroid hor-
mone concentrations (free T4 [fT4], TT4, total T3 [TT3], and free T3
[fT3]) were considered to be low or at the low end of the reference
interval.7 Although this study was the first prospective study that
evaluated the use of thyroid hormones for the treatment of aggres-
sion in dogs without concurrent behavioral treatment, the assays used
for measurement of serum concentrations of fT4 and TSH were not
specified. Furthermore, TT4 concentration might decrease below the
reference interval as much as 20% of the time in euthyroid dogs and
could be affected by time of the day, breed, age, season, temperature,
nonthyroidal illnesses, and drugs.46–50
Thyroid status also affects the turnover of monoamines, specifi-
cally serotonin, in several centers of the central nervous system.17,18
Serotonin has been associated with what has previously been called
“dominance aggression” in dogs, and the serotonin 2A receptor has
been demonstrated to be a valid biomarker for aggressive and anxious
behavior in dogs.10–13,15,51,52 In our study, the serum concentration of
serotonin during thyroid supplementation was not significantly differ-
ent from baseline. Studies in rats have shown a lesser effect of thyroid
status on serotonin turnover in the adult as opposed to the neonatal
brain.18 In humans, the role of thyroid hormones on serotonin
concentrations and responsiveness to serotonin-modulating drugs has
not been consistently demonstrated.38
Serotonin in the blood predominantly is stored in platelets and is
easily released during sample preparation.53 In this study, serotonin
was measured in serum using an ELISA test that has been validated
previously for dogs.33 Although the concentration of neurotransmit-
ters is best measured in the CSF, in humans, using novel methods,
good correlation between platelet and CSF concentrations was
shown.54 Although these techniques have not been validated for
dogs, studies comparing the serotonin concentrations of aggressive
and nonaggressive dogs effectively managed to document significant
differences in the serotonin concentrations using serum.11,13 With
ELISA, serotonin in dogs showing aggressive behavior also has been
reliably evaluated in plasma, platelets, and CSF.55,56
Daily fluctuations in the circulating serotonin concentration are
well recognized.57 Although advanced laboratory techniques manage
to minimize the effect of these fluctuations on the overall measured
serotonin concentration, these techniques are not currently validated
in dogs.54 To avoid the effect of daily fluctuations on serotonin mea-
surements, all blood collections were scheduled at the same daily time
points, between 9 and 11 AM. Daily variations of serotonin in dogs
have not been examined, but have been described in young horses, in
which the highest daily concentrations of serotonin were measured in
platelet-poor plasma in the late afternoon and the lowest concentra-
tions occurred during the early morning hours.58 Similar to horses,
humans with depression had their lowest serotonin concentrations
measured during morning hours and the highest concentrations mea-
sured in the afternoon.59
Another neuroprotein that has been shown to be affected by thy-
roid hormones is PRL.19 In our study, PRL concentrations after
6 weeks and 6 months of thyroid supplementation were not signifi-
cantly different compared to concentrations before treatment. Prolac-
tin was measured in plasma using a heterologous radioimmunoassay,
which has been validated previously in dogs.34 It has long been recog-
nized, based on classic experiments, that acute injection of serotonin
or its precursor, 5-hydroxytryptophan, stimulates PRL release.60 Indi-
viduals who have a low PRL response to serotonergic agonists express
more frequent aggressive signaling compared with individuals with a
high PRL response.61 In addition to serotonin, TRH also has been
shown to stimulate PRL secretion and PRL gene expression.19 With
thyroid hormone supplementation, TSH and TRH are normally down-
regulated via feedback mechanisms mediated by thyroid hormones.62
With regard to TRH-associated release of PRL, decreased TRH would
be expected to result in a decreased PRL concentration and conse-
quently decreased aggression. Thyrotropin-releasing hormone was
not measured in our study, and PRL remained unchanged after thyroid
hormone supplementation. Although a direct link among thyroid hor-
mones, serotonin, TRH, and PRL was not examined in our study, based
on our findings and in contrast to older reports, PRL might not play
such an important role in the modulation of dogs’ behavior as initially
assumed.19 Similar contradictory conclusions are found in the human
medical literature, with some studies documenting hyperprolactinemia
in hypothyroid women with aggressive behavior or mood disorders
and other studies failing to yield comparable conclusions.21,22
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Our study contributes important insight into the role of thyroid
hormone supplementation on behavior in dogs. However, the main
limitations are a small number of dogs, lack of a control group, and use
of a standardized behavioral questionnaire as opposed to individual
consultation with a behaviorist. The CBARQ provides a quantitative
score for a specific predetermined set of behavioral signs, and there-
fore, in a setting such as this one in which a change or a follow-up of
behavior is required, small or specific behavioral alterations could go
undetected.27 Despite being used in different research settings, to our
knowledge, the sensitivity and specificity of this tool for the examina-
tion of different behavioral characteristics of dogs have not been
examined. The lack of behavioral changes after 6 months of thyroid
supplementation in this group of dogs may be ascribed to the lack of
sensitivity of the behavioral questionnaire. The CBARQ also is an
owner-based questionnaire; therefore, a lack of objective and consis-
tent evaluation of the behavior during follow-up of these dogs is pos-
sible. The owners completed a new questionnaire during each visit
without seeing their scores from the previous questionnaire. It would
be interesting to speculate if the scoring at 6 months would be differ-
ent if the owners were allowed to directly compare the 6-month and
the 6-week questionnaires. Some of the 6-month questionnaires con-
tained owners' comments indicating that no change in the overall
behavior was documented since the last visit, but the scoring of the
behavioral categories to which the owners referred was different. Fur-
thermore, when evaluating the change in the behavior at 6 months,
owners were most likely comparing dogs' behavior with the 6-week
period and not the time before treatment was started. This could
explain why the activity level, which initially was increased, was con-
sidered as being not substantially increased at 6 months' time.
None of the dogs in our study had abnormal behavior or abnormal
concentrations of serotonin or PRL that would allow us to observe
potential improvement of these abnormalities with thyroid hormone
supplementation. In this regard, we cannot exclude a beneficial effect
of levothyroxine for treatment of dogs with increased irritability and
unprovoked aggression towards animals and people. Future studies
should aim at including hypothyroid dogs with these problems.
Observational studies in veterinary medicine and studies in
human medicine, although inconsistent, have documented an influ-
ence of thyroid antibodies in mental disorders and individual response
to thyroid hormone supplementation.38,43 Measurement of thyroglob-
ulin antibodies (TgAA) and free T4 in this cohort of dogs and future
studies would be interesting and also useful in dog breeds known to
be affected by autoimmune thyroiditis (ie, Doberman Pinchers), 1 of
which also was included in our study. However, to properly establish
the effect of autoimmune thyroid disease on brain function, behavior,
and thyroid hormone supplementation, advanced neuroimaging and
measurement of antibody reactivity against brain tissue would be
required and can be explored in future research.63,64 It also would be
useful to perform a neurological examination in this cohort of dogs
because it would allow us to evaluate the status of the central and
peripheral nervous system, both of which can be affected by hypothy-
roidism. However, because the majority of dogs included in our study
were recruited from first opinion practices, doing so would not be
possible and would not provide an additional therapeutic benefit for
these dogs.
Although larger studies and use of a control group are needed,
our study provided a standardized evaluation of the behavior and neu-
rohormonal status of dogs treated with thyroid hormones.
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